NCT01868048撤回3 期
A Phase 3 Dose Response Study to Assess the Safety and Efficacy of Nabiximols Oromucosal Spray (Sativex) in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis.
GW Research Ltd0 个研究点开始时间: 2013年6月4日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 主要终点
- Physician Global Impression of Change (PGIC) questionnaire
研究概览
简要总结
The purpose of this study is to determine the effective dose range and to demonstrate a non-effective dose range of Sativex compared with placebo in relieving symptoms of spasticity due to multiple sclerosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to give written informed consent.
- •The subject is at least 18 years of age or older.
- •Diagnosed with any disease sub-type of multiple sclerosis of at least six months duration.
- •Spasticity due to multiple sclerosis of at least six months duration, which is not wholly relieved with current anti-spasticity therapy, and which is expected to remain stable for the duration of the study.
- •Subject must be receiving at least one of the following anti-spasticity therapies to be eligible: Baclofen, Tizanidine, Clonazepam, Diazepam, Dantrolene.
- •Subject is willing to maintain anti-spasticity medication at a stable dose for the duration of the study and should be stable for 30 days prior to screening.
- •If the subject is currently taking disease-modifying medication, this must be at a stable dose for at least three months prior to the screening visit; the dose must also remain stable for the duration of the study.
排除标准
- •Has previously used Nabiximols or Sativex.
- •The subject is currently using or has used cannabis or cannabinoid based medications within 30 days of study entry and is unwilling to abstain for the duration of the study.
- •Any history or immediate family history of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition.
- •In the opinion of the Investigator, any known or suspected history of a substance abuse disorder (including opiate abuse), current heavy alcohol consumption (more than 60g of pure alcohol per day for men, and more than 40g of pure alcohol per day for women), current use of an illicit drug or current non prescribed use of any prescription drug that should exclude the subject from participation.
- •Has poorly controlled epilepsy or recurrent seizures (i.e. one or more seizure during the last year).
- •Any known or suspected hypersensitivity to cannabinoids or any of the excipients of the study medication.
- •Has experienced myocardial infarction or clinically significant cardiac dysfunction within the last 12 months or has a cardiac disorder that, in the opinion of the investigator would put the subject at risk of a clinically significant arrhythmia or myocardial infarction.
- •Has significantly impaired renal function as evidenced by a creatinine clearance lower than 50mL/min at Visit
- •Has significantly impaired hepatic function at Visit 1 (Alanine Aminotransferase >5 times upper limit of normal (ULN) or bilirubin (TBL) > 2 times ULN). If the Alanine Aminotransferase or Aspartate Aminotransferase >3 times ULN and the TBL >2 times ULN (or International Normalized Ratio >1.5), this subject should not enter the study.
- •Female subject of child-bearing potential and male subject whose partner is of child-bearing potential, unless willing to ensure that they or their partner use effective contraception or complete abstinence, for example, oral contraception, double barrier or intra-uterine device, during the study and for three months thereafter (however, a male condom should not be used in conjunction with a female condom as this may not prove effective).
- •Female subject who is pregnant, lactating or planning pregnancy during the course of the study and for three months thereafter.
- •Subjects who have received a non-approved investigational medicinal product within 30 days of Visit
- •Any other significant disease or disorder which, in the opinion of the investigator or sponsor, may either put the subject at risk because of participation in the study, or may influence the result of the study, or the subject's ability to participate in the study.
- •Travel outside the country of residence planned during the study.
- •Subjects previously enrolled into this study.
研究组 & 干预措施
Sativex
Experimental
Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.
Subjects received study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
干预措施: Sativex (Drug)
Placebo
Placebo Comparator
Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
干预措施: Placebo (Drug)
结局指标
主要结局
Physician Global Impression of Change (PGIC) questionnaire
时间窗: This is completed by the physician at each visit whilst using the study medication.
Change in mean Modified Ashworth Scale score from baseline to the end of treatment period.
时间窗: The Modified Ashworth Scale will be performed at each visit of the study
All 20 muscle groups were assessed for spasticity (using a 0-4 scale): 0= no increase in muscle tone to 4=considerable increase in muscle tone, passive movement is difficult. The score for all 20 muscle groups were added to give a total score out of 80. A decrease in score indicates an improvement in condition.
次要结局
- Change in mean sleep disruption (0-10 NRS) score from baseline to the end of treatment (Part B)(Recorded using IVRS daily diary every day)
- Change in mean spasm frequency (number of spasms per day) from baseline to the end of treatment (Part B).(Recorded using the IVRS daily day every day)
- Subject global impression of change (SGIC) questionnaire(To be completed by the patient at every visit during treatment)
- Carer Global Impression of Change Questionnaire(To be completed by the carer at every visit during the treatment period.)
研究者
相似试验
进行中（未招募）
不适用
Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood PressureHypertensionEUCTR2015-003329-32-Outside-EU/EEADaiichi Sankyo Pharma Development362
已完成
1 期
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic MalignanciesChronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)Acute Myeloid Leukemia (AML)Multiple Myeloma (MM)NCT00710528Gilead Sciences192
已完成
1 期
First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNHParoxysmal Nocturnal HemoglobinuriaNCT04330534BioCryst Pharmaceuticals168
招募中
3 期
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous NephropathyPrimary Membranous NephropathyNCT05696613Cerium Pharmaceuticals, Inc.148
已完成
1 期
Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)HIVHIV InfectionsNCT00850616Merck Sharp & Dohme LLC147